Q-Med AB invites to Q2 conference call

Media and analysts are invited to participate in a press conference at which the
report will be presented by Bengt Ågerup, President and CEO and Alexander
Kotsinas, CFO.

Time: Thursday July 22 at 11:30 a.m. CET.
Conference id: 87 04 10

To join the conference call dial: Sweden +46 8 505 201 14 or UK +44 (0)207
1620 177.

The slide presentation will be available atwww.q-med.com and
Investors/Presentations.

A recorded version of the presentation will be available for seven working days
on
tel: Sweden +46 8 505 203 33 or UK +44 (0)207 0314 064, access code 87 04 10.

Financial information 2010
October 22 - Interim Report January - September 2010

Queries should be addressed to:
Kristin Ermanbriks, IR Co-ordinator
Tel: +46 70 974 90 71


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q‑Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web:
www.q-med.com.


[HUG#1430970]